Molecular diagnostic assay modeling and quality control optimization for robust personalised cancer risk assessment

BioLizard supported Mdxhealth in developing a robust prostate cancer risk scoring model and optimizing triplex assay QC. By refining analytics, SOPs, and QC workflows, we enhanced predictive accuracy, reproducibility, and operational efficiency for personalized diagnostics.

Mdxhealth is a front runner in epigenetic research with a proven track record of identifying, developing, validating and delivering molecular diagnostic assays. They provide functional genomic data that can be used for personalised cancer risk assessment, with specific focus on prostate cancer.

Teamwork

Project 1 overview: Molecular diagnostic assay modeling

BioLizard assisted with development and optimisation of a robust model to calculate patient risk score for prostate cancer based on clinical biomarkers and other clinical features.

Wet lab

Project 2 overview: Molecular diagnostic triplex assay QC optimisation

The goal was to optimize the client’s current qualification of reagents and equipment. Instead of a head-to-head approach, we developed a QC panel that can be used in each run to see if they fall in between the expected QC ranges.

“We were very pleased with the work BioLizard did. The BioLizard team were very flexible and took the necessary time to fully understand our needs. Their tailored service allowed us to draw meaningful conclusions from our data.” – Mdxhealth

Our approach

Molecular diagnostic assay model

  • Model building to optimize clinical assay and patient risk score predictions based on a clinical biomarker panel
  • Leverage advanced analytics to develop robust and personalized patient risk scoring algorithms
  • Write SOPs
  • Calculate performance on clinical cohorts

Molecular diagnostic triplex assay QC optimisation

  • Based on historical data, develop expected range to be used as QC range
  • Develop criteria for releasing new items (new reagent batch and/or equipment)
  • For day-to-day QC: Analyze calibrator values, generate expected range + compare different setups

Results

SOPs
  • Provided detailed SOPs
  • Created a robust patient risk scoring model
  • Identified a potential breakthrough biomarker
  • Provided detailed model documentation for NY State Dept. of Health Review
QC
  • Day–to-day QC with robust ranges for better reproducibility and quality with less time, waste, and reagents
  • Improved research efficiency & capture of largest market share

For more information contact us today!

https://139582766.hs-sites-eu1.com/hs-web-interactive-139582766-76449037512

Work was performed in collaboration with Mdxhealth.

mdxhealth-logo-full-color-rgb
Paul Vauterin Moves from CTO to COO at BioLizard

Paul Vauterin Moves from CTO to COO at BioLizard

Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.

Beyond animal testing in drug development

Beyond animal testing in drug development

For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])